Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 21:344:e4181.
doi: 10.1136/bmj.e4181.

Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2

Gary S Collins  1 , Douglas G Altman
Affiliations

Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2

Gary S Collins et al. BMJ. .

Abstract

Objective: To evaluate the performance of the QRISK2-2011 score for predicting the 10 year risk of cardiovascular disease in an independent UK cohort of patients from general practice and to compare it with earlier versions of the model and a National Institute for Health and Clinical Excellence version of the Framingham equation.

Design: Prospective cohort study to validate a cardiovascular risk score with routinely collected data between June 1994 and June 2008.

Setting: 364 practices from the United Kingdom contributing to The Health Improvement Network (THIN) database.

Participants: Two million patients aged 30 to 84 years (11.8 million person years) with 93,564 cardiovascular events.

Main outcome measure: First diagnosis of cardiovascular disease (myocardial infarction, angina, coronary heart disease, stroke, and transient ischaemic attack) recorded in general practice records.

Results: Results from this independent and external validation of QRISK2-2011 indicate good performance data when compared with the NICE version of the Framingham equation. QRISK2-2011 had better ability to identify those at high risk of developing cardiovascular disease than did the NICE Framingham equation. QRISK2-2011 is well calibrated, with reasonable agreement between observed and predicted outcomes, whereas the NICE Framingham equation seems to consistently over-predict risk in men by about 5% and shows poor calibration in women.

Conclusions: QRISK2-2011 seems to be a useful model, with good discriminative and calibration properties when compared with the NICE version of the Framingham equation. Furthermore, based on current high risk thresholds, concerns exist on the clinical usefulness of the NICE version of the Framingham equation for identifying women at high risk of developing cardiovascular disease. At current thresholds the NICE version of the Framingham equation has no clinical benefit in either men or women.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

Figures

None
Fig 1 Observed versus predicted 10 year risk of cardiovascular disease (CVD)
None
Fig 2 Observed and predicted 10 year risk of cardiovascular disease (CVD) by age group and sex
None
Fig 3 Decision curves for participants aged 34 to 75 years in The Health Improvement Network
See this image and copyright information in PMC

Comment in

References

    1. World Health Organization. Cardiovascular diseases (CVDs). Fact sheet No 317. WHO, 2011. www.who.int.
    1. Department of Health. Putting prevention first—vascular checks: risk assessment and management. Department of Health, 2008.
    1. National Institute for Health and Clinical Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2008.http://guidance.nice.org.uk/CG67. - PubMed
    1. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8. - PubMed
    1. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 1997;297:611-9. - PubMed